Among the GLP-1RAs, semaglutide is the only GLP-1 analog being investigated in a dedicated phase 3 clinical trial to assess its impact on kidney outcomes in patients with T2D and CKD (141). This evidence concerns the gene GLP1R and chronic kidney disease.